Buyout Desk
Platform

Frazier Healthcare Partners completes majority investment in ATUM

Frazier Life Sciences and ATUM's founders and management joined the investment in the Newark, California-based bioengineering company. Terms were undisclosed.

Target
ATUM
Buyer
Frazier Healthcare Partners
Status
Completed

Frazier Healthcare Partners said it has completed its majority investment in ATUM, made in partnership with co-investors including Frazier Life Sciences and ATUM's existing founders and management team. The transaction was announced as completed on November 17, 2026, and no value was disclosed.

ATUM was originally founded as DNA2.0 in 2003 and is based in Newark, California. It pairs machine learning with gene design, protein optimization and cell line development through its Leap-In Transposase platform, supplying manufacturing scale-up support to biopharma companies. Jeremy Minshull continues as CEO, and Frazier Executive in Residence Milton Boyer joins the board as Executive Chair.

Minshull said the partnership will let ATUM expand capacity, grow infrastructure and innovate faster. Baird acted as ATUM's exclusive financial adviser and Paul Hastings as its legal counsel. William Blair and Goodwin Procter advised Frazier.

Background

Business
Bioengineering company providing machine learning-driven gene design, protein optimization and cell line development services to biopharma companies
Deal type
Platform
Headquarters
Newark, California
Advisers
  • Baird financial adviser to ATUM
  • Paul Hastings legal counsel to ATUM
  • William Blair financial adviser to Frazier Healthcare Partners
  • Goodwin Procter legal counsel to Frazier Healthcare Partners

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.

Frazier Healthcare Partners deal history